1. OC-0559: Predictors of Failures following Chimeric Antigen Receptor T-cell (CAR T) Therapy. (November 2020) Authors: Figura, N.; Jain, M.; Sim, A.; Dean, E.; Balagurunathan, Y.; Chavez, J.; Shah, B.; Khimani, F.; Lazaryan, A.; Davila, M.; Liu, H.; Kim, S.; Locke, F.; Robinson, T. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S311 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM. (23rd June 2022) Authors: Wang, Y.; Jain, P.; Locke, F.; Maurer, M.; Frank, M.; Munoz, J.; Dahiya, S.; Beitinjaneh, A.; Jacobs, M.; Mcguirk, J.; Vose, J.; Goy, A.; Andreadis, C.; Hill, B.; Dorritie, K.; Oluwole, O.; Deol, A.; Shah, B.; Paludo, J.; Wang, T. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE. (23rd June 2022) Authors: Bücklein, V.; Perez, A.; Iacoboni, G.; Rejeski, K.; Holtick, U.; Penack, O.; Kharboutli, S.; Blumenberg, V.; Ackermann, J.; Frölich, L.; Johnson, G.; Patel, K.; Arciola, B.; Schmidt, C.; Albanyan, O.; Gödel, P.; Hoster, E.; Bullinger, L.; Mackensen, A.; Locke, F. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US). (23rd June 2022) Authors: Locke, F.; Hu, Z.-H.; Gerson, J.; Frank, M. J.; Budde, L. E.; Wang, M.; Logan, B.; Kloos, I.; Siddiqi, R.; Shah, J.; Xu, H.; Pasquini, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1336 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL. (23rd June 2022) Authors: Rejeski, K.; Albanyan, O.; Iacoboni, G.; Bücklein, V.; Blumenberg, V.; Penack, O.; Bethge, W.; Völkl, S.; Perez, A.; Carpio, C.; Schmidt, C.; Müller, N.; Reid, K.; Faramand, R.; Davila, M.; Bullinger, L.; Locke, F.; von Bergwelt-Baildon, M.; Mackensen, A.; Barba, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PO-1075 Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell Lymphoma. (August 2021) Authors: Figura, N.; Sim, A.; Dahiya, S.; Lutfi, F.; Rapoport, A.; Mohindra, P.; Dohm, A.; Chavez, J.; Shah, B.; Khimani, F.; Lazaryan, A.; Davila, M.; Bachmeier, C.; Nishihori, T.; Liu, H.; Kim, S.; Locke, F.; Jain, M.; Robinson, T. Journal: Radiotherapy and oncology Issue: Volume 161(2021)supplement Page Start: S894 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗